Asia Pacific Uveitis Treatment Market By Drug Class By Disease Type By Distribution Channel By Country, Industry Analysis and Forecast, 2019 - 2025

Asia Pacific Uveitis Treatment Market By Drug Class By Disease Type By Distribution Channel By Country, Industry Analysis and Forecast, 2019 - 2025

  • March 2020 •
  • 90 pages •
  • Report ID: 5885876 •
  • Format: PDF
The Asia Pacific Uveitis Treatment Market would witness market growth of 6.7% CAGR during the forecast period (2019-2025).

Anti-inflammatory medications are available in the form of eye drops, pills, or injection medicine. Anti-inflammatory medication eye drops may not penetrate well to the back of the eye, so this form of treatment is not recommended for posterior uveitis. In the case of intermediate or posterior uveitis, and if topical corticosteroid has not operated, injections or injections of corticosteroids are used to minimize inflammation. On the other hand, the segment of immunotherapy & targeted therapies is projected to see the highest growth in the market due to a rise in demand for ideal therapies for uveitis treatment. In the market for uveitis treatment, there are immunosuppressant medications such as azathioprine, cyclosporine, methotrexate, mycophenolate, and others.

Corticosteroid treatments have predominantly shaped the bulk of the uveitis market. The Asia-Pacific uveitis market, which is AbbVie’s Humira (adalimumab), currently only provides one targeted treatment. The late-stage uveitis pipeline consists of the Opsiria of Santen and the CLS-TA of Clearside Biomedical, which is predicted to be extremely lucrative and solve some of the unmet needs. These new drugs will broaden the options available for treating patients with uveitis and contribute to overall market growth by introducing new therapeutic pathways, including new drug delivery routes and novel, non-corticosteroid drug molecules.

Based on Drug Class, the market is segmented into Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online stores. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.

Scope of the Study

Market Segmentation:

By Drug Class

• Anti-inflammatory

• Immunotherapy & Targeted Therapies

• Antimicrobial Drugs

• Other Drug Class

By Disease Type

• Anterior Uveitis

• Posterior Uveitis

• Intermediate Uveitis

• Panuveitis

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online stores

By Country

• China

• Japan

• India

• South Korea

• Singapore

• Malaysia

• Rest of Asia Pacific

Companies Profiled

• AbbVie, Inc.

• Alimera Sciences, Inc.

• Enzo Biochem, Inc.

• Amgen, Inc.

• Bausch Health Companies, Inc.

• Clearside Biomedical, Inc.

• EyePoint Pharmaceuticals, Inc.

• Santen Pharmaceutical Co., Ltd.

• TopiVert Ltd.

• Novartis AG

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free